Quarterly report · Q1
4483.TEDINET S100P0TK
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.8bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥4.5bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥823m | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥806m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥765m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥538m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥759m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥538m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥63.3bn | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥57.3bn | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥31.9bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥31.4bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥31.4bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥28.3bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥10.1bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥17.9bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥805m | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥3.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥909m | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.4bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥13.55 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥9.62 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥12.73 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥9.03 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 49.7% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.4% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥58m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥58m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥90m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥910m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥869m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥41m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥47m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥17m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥439m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥5.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥58m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥35m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥35m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥74m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥782m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥755m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥27m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥49m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥2.8bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥858m |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.0bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥1.0bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥330m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥4.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥4.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥35m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥1.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 683
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividends ss IFRS | CurrentYTDDuration | -565000000 | JPY |
| Increase decrease by business combination ss IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | － | JPY |
| Increase decrease by business combination ss IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | － | JPY |
| Increase decrease by business combination ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | － | JPY |
| Increase decrease by business combination ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | -15000000 | JPY |
| Increase decrease by business combination ss IFRS | CurrentYTDDuration | -15000000 | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | -4000000 | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | 4000000 | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | － | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration | － | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | -4000000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | -560000000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | -523000000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | -15000000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration | -539000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_OtherComponentsOfEquityIFRSMember | 15000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_RetainedEarningsIFRSMember | 9785000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 31416000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_NonControllingInterestsIFRSMember | -26000000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 31389000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 806000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 1120000000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 365000000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 444000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | 1077000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | 438000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -14000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -25000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -583000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -181000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -122000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | 323000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 1529000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 2119000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 0 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 0 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -13000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -13000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -710000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -1016000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 805000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 1089000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -36000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -180000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -189000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -318000000 | JPY |
| Payments for loans receivable inv cf IFRS | Prior1YTDDuration | － | JPY |
| Payments for loans receivable inv cf IFRS | CurrentYTDDuration | -150000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -1103000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |